Venetoclax, also known as ABT-199 or GDC0199, is an orally bioavailable, selective small molecule inhibitor of the anti-apoptotic protein Bcl-2, with potential antineoplastic activity. Venetoclax mimics BH3-only proteins, the native ligands of Bcl-2 and apoptosis activators, by binding to the hydrophobic groove of Bcl-2 proteins thereby repressing Bcl-2 activity and restoring apoptotic processes in tumor cells.
Ku, Yi-Yin; Chan, Vincent S.; Christesen, Alan; Grieme, Timothy; Mulhern, Mathew; Pu, Yu-Ming; Wendt, Michael D. Development of a Convergent Large-Scale Synthesis for Venetoclax, a First-in-Class BCL-2 Selective Inhibitor. Journal of Organic Chemistry. Volume 84. Issue 8. Pages 4814-4829. Journal; Online Computer File. (2019).
Peng, Lei; Huang, Xiongjiu; He, Wei; Tang, Lichang; Liu, Ling; Chen, Zhenming. Novel preparation method of venetoclax as B-cell lymphoma-2 (BCL-2) selective inhibitor by condensation and substitution, and product thereof. Assignee Chongqing Sansheng Industrial Co., Ltd., Peop. Rep. China. CN 109438441. (2019).
Ge, Min; Xu, Yunlei. Synthesis of Bcl-2 inhibitor of ABT-199. Assignee Nanjing Youjie Pharmatech Co., Ltd., Peop. Rep. China. CN 104370905. (2015).
